Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia

Supplemental figure 1. Flow chart for sample availability of patients included in our study and their outcome. Supplemental figure 2. Supplemental figure 3. Size of LSC nodes in CD34+CD38- subpopulation in AML-CD34+ and AMLCD34- populations. Mann-Whitney test. Supplemental figure 4. LSC phenotypic profiles according to MRD status. Normalized MFI of CD34, CD38, CD45RA, CD135 and CD133 in LSC nodes used to measure LSC MRD. Mann-Whitney tests. Supplemental figure 5. Landmark analysis at 6 months of the impact of HSCT according to MRD status. Supplemental figure 6. Evaluation of immunophenotypic markers in chemoresistant and chemosensitive AML patients at diagnosis. Supplemental figure 7. Evaluation of LSC phenotypic markers in clinically relevant AML patients in relation to Figure 4.